Pharmacology, Toxicology and Pharmaceutical Science
Lung Cancer
100%
Non Small Cell Lung Cancer
96%
Disease
59%
Cohort Study
58%
Epidermal Growth Factor Receptor
57%
Coronavirinae
46%
Symptom
38%
Osimertinib
37%
Combination Therapy
28%
Biological Marker
26%
Prospective Cohort Study
24%
Adverse Event
24%
Infection
23%
Malignant Neoplasm
22%
Asthma
19%
Discoidin Domain Receptor 2
18%
Irinotecan
18%
Chronic Obstructive Lung Disease
18%
Overall Survival
18%
Progression Free Survival
18%
SARS Coronavirus
18%
Dyspnea
18%
Chemotherapy
14%
Observational Study
13%
Phase II Trials
12%
Gefitinib
11%
Monotherapy
10%
Pharmacokinetics
10%
Cytotoxic Chemotherapy
9%
Nedaplatin
9%
Afatinib
9%
Effusion
9%
Long Term Exposure
9%
Active Metabolite
9%
Intrinsic Resistance
9%
Cetuximab
9%
6 [4 (4 Ethyl 1 Piperazinylmethyl)phenyl] 4 (Alpha Methylbenzylamino) 7h pyrrolo[2,3 D]pyrimidine
9%
Mouse Model
9%
Bromodomain Inhibitor
9%
RNA-Sequencing
9%
Pembrolizumab
9%
Genetically Engineered Mouse Strain
9%
Immunotherapy
9%
ABC Transporter
9%
Nuclease
9%
Erlotinib
9%
Paclitaxel
9%
Vaccination Policy
9%
microRNA 375
9%
Deoxythioguanosine
9%
Medicine and Dentistry
Lung Cancer
78%
COVID-19
67%
Non Small Cell Lung Cancer
62%
Computer Assisted Tomography
42%
Epidermal Growth Factor Receptor
32%
Biological Marker
30%
Lung Adenocarcinoma
27%
Cohort Analysis
27%
Retrospective Cohort Study
21%
Immune Checkpoint Inhibitor
18%
Artificial Respiration
17%
Cancer Cell
16%
Neoplasm
16%
Disease
15%
Targeted Therapy
15%
Elderly Patient
14%
Overall Survival
14%
Dyspnea
13%
Malignant Neoplasm
13%
Sequela
12%
Lung Cancer Cell Line
12%
Diarrhea
12%
Diagnosis
11%
Pemetrexed
11%
Bevacizumab
11%
Disease Severity
11%
Molecularly Targeted Therapy
10%
Prognostic Factor
10%
Multivariate Analysis
10%
Odds Ratio
10%
Cytotoxic Chemotherapy
9%
Atezolizumab
9%
Adverse Event
9%
Oncogene
9%
Auditory Hallucination
9%
Glycyrrhizic Acid
9%
Organizing Pneumonia
9%
Distress Syndrome
9%
Mediator
9%
Nedaplatin
9%
Organoid
9%
Adaptive Response
9%
Swallowing Function
9%
Hypocalcaemia
9%
Discoidin Domain Receptor 2
9%
Solid Malignant Neoplasm
9%
Postcovid Syndrome
9%
Carcinomatous Peritonitis
9%
Visual Hallucination
9%
Cell Therapy
9%
Keyphrases
COVID-19
44%
Long COVID
40%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
37%
Japan
36%
Confidence Interval
34%
Non-small Cell Lung Cancer (NSCLC)
32%
Non-small Cell Lung Cancer Patients
25%
Multicenter Cohort Study
23%
Osimertinib
18%
Combination Therapy
18%
Chest CT
18%
Dyspnea
17%
Long COVID Symptoms
16%
Adjusted Odds Ratio
15%
Mechanical Ventilation
15%
Odds Ratio
14%
EGFR mutation
13%
Disease Severity
13%
Clinical Characteristics
12%
Previously Treated Patients
11%
Phase II Trial
11%
Immune Checkpoint Inhibitors
11%
Risk Factors
10%
Long Coronavirus Disease
10%
Retrospective Cohort Study
10%
Clinical Efficacy
10%
Japanese Patients
10%
Lung Cancer
10%
Diarrhea
10%
Synergistic Efficacy
9%
FOXD1
9%
Phase I Study
9%
Longitudinal Assessment
9%
COVID-19 Sequelae
9%
Benign Pulmonary Diseases
9%
Erlotinib
9%
Exon 20 mutation
9%
Nedaplatin
9%
Afatinib
9%
CPT-11
9%
Oncomine Dx Target Test
9%
Stable COPD
9%
Impaired Swallowing
9%
Therapeutic Outcome
9%
EGFR Exon 20 Insertion mutations
9%
Prognostic Understanding
9%
Immune Inhibition
9%
Japanese Nation
9%
UFMylation
9%
Peritoneal Carcinomatosis
9%